Carmell Other Current Liab from 2010 to 2024

CTCX Stock   0.28  0.02  7.69%   
Carmell Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Carmell Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.30 and arithmetic mean of  9,552,273. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
32.6 M
Current Value
34.3 M
Quarterly Volatility
9.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Carmell Therapeutics Correlation against competitors.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.

Latest Carmell Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Carmell Therapeutics over the last few years. It is Carmell Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Carmell Other Current Liab Regression Statistics

Arithmetic Mean9,552,273
Geometric Mean7,171,027
Coefficient Of Variation102.35
Mean Deviation6,375,997
Median6,208,458
Standard Deviation9,776,361
Sample Variance95.6T
Range32.4M
R-Value0.54
Mean Square Error72.4T
R-Squared0.30
Significance0.04
Slope1,190,585
Total Sum of Squares1338.1T

Carmell Other Current Liab History

202434.3 M
202332.6 M
20221.9 M

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities32.6 M34.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.